NEW YORK, Sept. 27 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today provided an update to its development pipeline, which includes 118 programs from Phase 1 through registration. The updated pipeline continues to reflect Pfizer's ongoing investment in high-priority disease areas with considerable unmet medical need.
"We continue to be confident in the progression of our late-stage pipeline and have advanced three compounds into registration since our last portfolio update," said Ian Read, president of Pfizer's Worldwide Biopharmaceutical Businesses. "We have a strong pipeline with programs in development across important therapeutic areas including oncology, neuroscience and inflammation. We remain committed to growing our biologics and vaccines development programs."
"Building on the rapid integration of Pfizer and Wyeth, the new Pfizer brings a wealth of scientific approaches and technologies to our key investment areas, and we are developing novel product candidates across all phases of development," said Mikael Dolsten, MD, PhD, president of Pfizer's Worldwide Research and Development. "We are leveraging the best product assets of our legacy organizations and driving important steps forward in strategy and method to deliver a portfolio of next generation medicines and vaccines."
Pfizer now has 118 programs in Phase 1 through registration, compared to 133 programs at its last pipeline update in January, 2010. This reflects 25 programs that are new or have advanced along the pipeline and 31 programs that have been discontinued since the last update. The current pipeline includes 26 programs in Phase 3 and nine programs in registration, as well as 27 biologics and four vaccines across
|SOURCE Pfizer Inc.|
Copyright©2010 PR Newswire.
All rights reserved